CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK ...Middle East

This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission. The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in...

Read More Details
Finally We wish PressBee provided you with enough information of ( CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK )

Also on site :

• Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release
• Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
• Nuclear agency head warns of radiological and chemical contamination inside Iran’s main nuclear site